Search Results

Quotient Therapeutics’ platform targets somatic mutations, which the startup contends can help identify a broader scope of genes potentially associated with disease phenotypes. Wednesday’s agreement is part of an existing partnership between Pfizer and Flagship Pioneering.

Quotient Limited announced that it has given formal notice to the Nasdaq Stock Market LLC of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market.

Quotient Limited announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient’s MosaiQ platform.

Quotient Limited, a commercial-stage diagnostics company, announced that it will effect a one-for-40 reverse stock split of its ordinary shares, nil par value that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced it was selected by the World Economic Forum to join their New Champions Community.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient’s MosaiQ solution.

Quotient Limited announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.